Upacicalcet
As of the edition of 20 October 2026, Upacicalcet is a small molecule: marketed, first approved in 2021 (JP); acts on CASR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Upasita
- First approved
- 23 June 2021 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Sanwa Kagaku Kenkyusho
- Registered trials
- 4, 0 stopped early
- Disease areas
- Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Upacicalcet.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CASR | Extracellular calcium-sensing receptor | P41180 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 4 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanwa Kagaku Kenkyusho | Applicant and Lead sponsor of trials | 2018 to now |